Page 1,215«..1020..1,2141,2151,2161,217..1,2201,230..»

New ‘molecular switch’ allows control of gene therapy doses – International Business Times, Singapore Edition

Posted: December 25, 2019 at 12:45 pm

Man who implanted chips in his hand.

Paving the way for solving a major safety issue associated with gene therapies, scientists have developed a special molecular switch that could be embedded into such therapies to allow doctors to control dosing. The feat, published in the journal Nature Biotechnology, offers gene therapy designers what may be the first viable technique for adjusting the activity levels of their therapeutic genes.

The lack of such a basic safety feature has helped limit the development of gene therapy, which otherwise holds promise for addressing genetically based conditions.

"I think that our approach offers the only practical way at present to regulate the dose of a gene therapy in an animal or a human," said lead researcher Michael Farzan from the Scripps Research Institute in Jupiter in Florida, US.

Gene therapies work by inserting copies of a therapeutic gene into the cells of a patient, if, for example, the patient was born without functional copies of the needed gene.

The strategy has long been seen as having enormous potential to cure diseases caused by defective genes.

It could also enable the steady, long-term delivery to patients of therapeutic molecules that are impractical to deliver in pills or injections because they don't survive for long in the body.

However, gene therapies have been viewed as inherently risky because once they are delivered to a patient's cells, they cannot be switched off or modulated.

As a result, only a handful of gene therapies have been approved to date.

In this study, the researchers demonstrated the power of their new switching technique by incorporating it into a gene therapy that produces the hormone erythropoietin, used as a treatment for anaemia.

They showed that they could suppress expression of its gene to very low levels with a special embedded molecule, and could then increase the gene's expression, over a wide dynamic range, using injected control molecules called morpholinos that the US Food and Drug Administration has found to be safe for other applications.

View original post here:
New 'molecular switch' allows control of gene therapy doses - International Business Times, Singapore Edition

Posted in Gene therapy | Comments Off on New ‘molecular switch’ allows control of gene therapy doses – International Business Times, Singapore Edition

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment -…

Posted: December 25, 2019 at 12:44 pm

I want to congratulate our team for their success in developing SB-525 through to this important milestone where we have handed over the IND to Pfizer for Phase 3 development, said Sandy Macrae, CEO of Sangamo. We are thrilled to be in a partnership where both parties have cooperated to accelerate study timelines, resulting in completion of the IND transfer ahead of schedule. Pfizer and Sangamo are united in our common interest to help patients with Hemophilia A and will do everything that we can to safely and expeditiously advance this promising gene therapy candidate for patients in need.

The SB-525 collaboration was established in May 2017. Under the terms of the collaboration agreement, Sangamo has been responsible for Phase 1/2 clinical development. Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525. Sangamo is eligible to receive total potential milestone payments of up to $300 million for the development and commercialization of SB-525, and up to $175 million for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration. Sangamo will, additionally, receive tiered royalties starting in the low teens and up to 20% of annual net sales of SB-525.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Sangamo Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of United States securities law. These forward-looking statements include, but are not limited to, the therapeutic potential of SB-525; the enrollment of clinical trials and global registration and commercialization and the expected timing for milestones the expected benefits of Sangamos collaboration with Pfizer; the anticipated capabilities of Sangamos technologies; and other statements that are not historical fact. These statements are based upon Sangamos current expectations and speak only as of the date hereof. Sangamos actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to dependence on the success of clinical trials; the uncertain regulatory approval process; the costly research and development process, including the uncertain timing of clinical trials; whether interim, preliminary or initial data from ongoing clinical trials will be representative of the final results from such clinical trials; whether the final results from ongoing clinical trials will validate and support the safety and efficacy of product candidates; the risk that clinical trial data are subject to differing interpretations by regulatory authorities; the potential inability of Sangamo and its partners to advance product candidates into registrational studies; Sangamos reliance on itself, partners and other third-parties to meet clinical and manufacturing obligations; Sangamos ability to maintain strategic partnerships; competing drugs and product candidates that may be superior to Sangamos product candidates; and the potential for technological developments by Sangamo's competitors that will obviate Sangamo's gene therapy technology. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamos operations. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on or about November 6, 2019. Except as required by law, we assume no obligation, and we disclaim any intent, to update these statements to reflect actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191223005185/en/

Read more here:
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment -...

Posted in Gene therapy | Comments Off on Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment -…

Viewpoint: EU should take a lead in enforcing the corporate social responsibility of gene therapy manufacturers – Science Business

Posted: December 25, 2019 at 12:44 pm

Gene therapy is providing unprecedented hope for growing numbers of patients and families. This game changer in medicine restores vision in babies born with congenital blindness, reconstitutes defences against infection in inherited immunodeficiencies and offers the perspective of curing the devastating neuromuscular disease, spinal muscular atrophy.

Gene therapy is also removing the need for repeat blood transfusions in adolescents with the inherited blood disorder, beta-thalassemia. Meanwhile, in oncology, CAR-T therapies, involving genetic modifications of a patients own immune cells, are proving life-saving for children or adults with certain types of blood cancers.

All these revolutionary treatments are now approved by regulatory agencies in Europe or the US. Unfortunately, they carry astronomical price tags which prevent their effective delivery to patients. As one case in point, Bluebird Bios Zynteglo for treating beta-thalassemia, has a list price of 1.57 million.

Can high prices be justified?

Gene therapy manufacturers defend their prices by pointing to high development and manufacturing costs, small markets, and unique therapeutic effectiveness as compared to the current standard of care. However, R&D costs are kept secret, and higher numbers of patients eligible for a given therapy do not translate into lower prices.

Indeed, several arguments the manufacturers put forward are dubious or even far-fetched. As of today, claims that a single administration of a gene therapy product will ensure a lifelong cure are simply not supported by the scientific evidence.

Likewise, value-based pricing is often misconceived. As stated by the US Institute for Clinical and Economic Review in its 2017 white paper on gene therapy, the established value of a treatment reflects the maximum price society might be prepared to pay for it - but should not dictate the price that is actually paid. In an ideal world, actual prices should provide market-consistent returns for shareholders and sufficient incentive to innovate.

The EU, a pioneer in gene therapy

European scientists, institutions and charities have been central to the development of gene therapy. The world's first successful clinical trial was reported in 2000 by Alain Fischer and his team at Necker Hospital in Paris, while the first authorisation of a gene therapy product in a regulated market was granted by the European Medicines Agency in 2012.

According to the Cordis database of EU-supported research, 86 gene therapy projects for rare diseases had funding from the European Commission during the FP7 (2007-2013) and Horizon 2020 (2014-2020) research programmes. One can estimate that overall more than 1 billion has been invested in this area by the EU Commission, member states and not-for-profit organisations.

To ensure European patients benefit from these achievements and investments, it is essential to ensure reasonable pricing of gene therapies. Laudable efforts are currently being made by the World Health Organization to increase transparency, and by some member states to join forces in negotiating prices, but such initiatives are unlikely to solve the current crisis as they do not address its root, namely that the sole objective of most gene therapy companies is to maximise the return on investment and shareholder value.

A way forward: enforcing the corporate social responsibility of gene therapy manufacturers

As I recently argued with Alain Fischer and the economist Mathias Dewatripont in the journal Nature Medicine (November 25, 2019), now is the time to reflect on how to enforce the corporate social responsibility of gene therapy companies.

Among the measures we would like to see considered are the insertion of clauses into technology transfer agreements made between academic organisations receiving grants from the European Commission and for-profit companies to make reasonable pricing compulsory.

We also propose to make reimbursement of gene therapies by EU healthcare payers conditional on the companies which are commercialising these products being certified for their corporate social responsibility. This is in line with several commitments made recently by pharma companies. For example, in August 2019, the CEOs of US-based pharma companies signed the Business Roundtable Statement, affirming their commitment to generate value for all their stakeholders not just their shareholders.

Also in August, Novartis announced it had joined the Value Balancing Alliance, a body whose goal is to increase transparency around business decisions, work with external bodies to develop accounting frameworks, and shift priority from profit maximisation to optimising value creation.

Earlier this year, the pharmaceutical company Chiesi was certified as a Benefit Corporation, meaning its legally defined goals include positive social impact in addition to profit.

Of course, the effective implementation of such commitments and their translation into reasonable pricing policies will require both incentives and regulatory controls. The starting point should be a renewed multi-stakeholder conversation with industry, investors, regulators, payers and, of course, patients.

Professor Michel Goldman is Co-director of the I3h Institute at the Universit Libre de Bruxelles and former Executive Director of the EU Innovative Medicines Initiative.

Continued here:
Viewpoint: EU should take a lead in enforcing the corporate social responsibility of gene therapy manufacturers - Science Business

Posted in Gene therapy | Comments Off on Viewpoint: EU should take a lead in enforcing the corporate social responsibility of gene therapy manufacturers – Science Business

UPDATED: Sarepta cements its DMD throne with $1B+ gene therapy deal with mighty Roche – Endpoints News

Posted: December 25, 2019 at 12:44 pm

Sanofi was locked in a bidding war right up to the final moments of closing its $2.5 billion buyout of Synthorx, as it rushed to complete a deal this or another to bolster CEO Paul Hudsons new R&D vision before wrapping the year. By Synthorxs account, what began as routine partnership talks took a sharp turn into two weeks of intense negotiations in which the San Diego biotech was able to almost double the offer.

By moving swiftly and aggressively, Sanofi fended off three other suitors to pocket a slate of next-gen IL-2 drugs for cancer and autoimmune diseases as well as a synthetic biology platform. The pharma giant now takes over a pipeline whose most advanced asset it still in Phase I/II befitting an organization that now vows to get in early enough to change a treatment paradigm.

The initial meetings with Synthorx took place at all the usual places: ESMO 2018, JP Morgan and AACR 2019. Soon Sanofi R&D chief John Reed stepped in, but the smaller player continued to explore options with other companies at ASCO and BIO over the summer.

Unlock this story instantly and join 68,400+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See the rest here:
UPDATED: Sarepta cements its DMD throne with $1B+ gene therapy deal with mighty Roche - Endpoints News

Posted in Gene therapy | Comments Off on UPDATED: Sarepta cements its DMD throne with $1B+ gene therapy deal with mighty Roche – Endpoints News

VGXI adds RNA suite to tap cell and gene therapy – Bioprocess Insider – BioProcess Insider

Posted: December 25, 2019 at 12:44 pm

VGXI has set up an RNA pilot production suite at its facility in Woodlands, Texas citing growing demand from gene therapy developers.

The GMP-grade mRNA manufacturing unit will support customer projects from initial plasmid construction through linearization, in vitro translation, mRNA purification, and comprehensive quality control testing according to VGXI.

VGXI plans to launch clinical grade mRNA manufacturing services next year.

The RNA suite will be set up in Woodlands, near Houston. Image: iStock/gguy44

The pilot plant was set up as part of the VGXI licensing deal with the Houston Methodist Research Institute.

The CDMO said it will continue to work with the Institutes RNACore group a research team focused on RNA synthesis to set up a large-scale GMP mRNA production facility.

In a separate announcement VGXI said it has hired construction services company BE&K Building Group as Design-Build Partner for the initial phase of the manufacturing site.

It said the planned 240,000-square-foot facility will house multiple flexible production suites to support both DNA and RNA-based biopharmaceuticals at all phases of development through commercial supply.

The plant is expected to be operational in two to three years.

The investment is in keeping with the DNA vaccines partnership VGXI forged with Geneos Therapeutics earlier in the year.

The deal will see VGXI make the API, or core component of Geneos Therapeutics DNA vaccine product according to spokeswoman Christy Franco.

VGXI cited growth of the gene therapy sector as the basis for its investment in RNA capacity.

It said, A driving factor for both site selection and building design is available capacity to support VGXIs continued, future expansions to meet growing industry demand.

VGXI has identified and selected a suitable location for the construction project, with approval granted in November for a $1.2 million incentive during a special council meeting by the City of Conroe.

The Texan CDMO joins the growing list of contractors trying to tap the gene therapy sector. In recent months both Fujifilm and Cytovance have cited demand for gene therapy production services as an expansion driver.

The firms comments fit with the dynamics observed by the pharmaceutical research and manufacturers of America (PhRMA).

Accordingto the industry group, at present there are 289 cell and gene therapy products in development, which is a marked increase on previous years.

Read this article:
VGXI adds RNA suite to tap cell and gene therapy - Bioprocess Insider - BioProcess Insider

Posted in Gene therapy | Comments Off on VGXI adds RNA suite to tap cell and gene therapy – Bioprocess Insider – BioProcess Insider

Hormone Replacement Therapy Market Share Value Projected to Expand by 2019 2027 – Market Research Sheets

Posted: December 25, 2019 at 12:43 pm

Coherent Market Research adds Hormone Replacement Therapy Market Report provides an analytical assessment of the prime challenges faced by this Market currently and in the coming years, which helps Market participants in understanding the problems.

The Hormone Replacement Therapy Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on a global and regional level. This report studies the global Hormone Replacement Therapy Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Hormone Replacement Therapy Market by companies, region, type, and end-use industry.

Hormone Replacement Therapy Market Report covers the following major players: Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

Get Free Request Sample from Industry Experts @ https://www.coherentmarketinsights.com/insight/request-sample/2079

This Hormone Replacement Therapy market research study is a collection of insights that translate into a gist of this industry. It is explained in terms of a plethora of factors, some of which include the present scenario of this marketplace in tandem with the industry scenario over the forecast timespan.

The report is also inclusive of some of the major development trends that characterize the Hormone Replacement Therapy market. A comprehensive document in itself, the Hormone Replacement Therapy market research study also contains numerous other pointers such as the current industry policies in conjunction with the topographical industry layout characteristics. Also, the Hormone Replacement Therapy market study is comprised of parameters such as the impact of the current market scenario on investors.

Promising Regions & Countries Mentioned In The Hormone Replacement Therapy Market Report:

Get Free PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2079

Regional landscape:

How will the details provided in the report help prominent stakeholders?

The information that this study delivers, pertaining to the geographical landscape, is indeed rather vital.

As per the study, the topographical spectrum of this industry covers the geographies of North America, Europe, Asia-Pacific & Middle East and Africa.

The study, in detail, enumerates the overview of the regional scope with respect to the growth rate that is likely to be recorded by each region over the projected duration.

Other important aspects pertaining to the topographical reach that may prove important for buyers include the remuneration and the production volume with regards to each region. The market share which every region holds in the industry has also been provided.

Get Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2079

If you wish to want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

This post was originally published on Market Research Sheets

Go here to see the original:
Hormone Replacement Therapy Market Share Value Projected to Expand by 2019 2027 - Market Research Sheets

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Share Value Projected to Expand by 2019 2027 – Market Research Sheets

News digest prostate cancer MRI trial, drug delivery, cancer cures on Facebook and weight loss – Cancer Research UK – Science Blog

Posted: December 25, 2019 at 12:43 pm

Radiographers are responsible for taking MRI scans.

BBC News reports on a new large-scale trial that will test if MRI scans could be used to screen men for prostate cancer. The trial will invite 300 randomly selected men aged 50 to 75 years old to have a 10-minute MRI scan and a PSA blood test. Scientists are hoping to find out if using MRI in this way could help to flag men who have signs of prostate cancer without the need for a biopsy. Weve blogged before about how scientists are working to improve prostate cancer diagnosis.

A British woman is the first person in the world to receive a new treatment that aims to deliver high doses of chemotherapy directly to cancer cells. The treatment, which uses tiny clusters of bubbles and liquid droplets to enhance the delivery of chemotherapy, is part of a clinical trial being carried out in London thats looking to reduce the number of doses of chemotherapy and its side effects for cancer patients. Read the full story in The Metro.

A cheaper version of the breast cancer drug Herceptin has been approved by the World Health Organisation (WHO). This decision will make it possible for women in low-income countries to benefit from treatment. This type of hormone therapy blocks off certain cancers fuel supply. More on this in The Guardian.

Several Facebook groups promoting a dangerous skin cancer treatment have been banned from the social media channel, following concerns about sensational health claims. Groups were promoting a black salve paste, which they claimed had the ability to cure skin cancer by eating away at only cancerous cells. According to Buzzfeed News, the groups have been found to be in violation of Facebook rules that prohibit violent and criminal behaviour. Commenting on the story, experts strongly advised anyone considering taking an alternative or complimentary medicine to seek advice from a trained medical professional.

The Mail Online covers a study that says that post-menopausal women who are overweight could reduce their risk of breast cancer if they lose at least 20lbs. But the results present quite a complicated picture. Women who had sustainedweightloss only had a reduced cancer risk if they werent taking hormone replacement therapy (HRT). And because hormone replacement therapy can increase the risk of breast cancer too, its hard to untangle which risk factor is having an effect. Unfortunately, theres still not enough evidence to know what effect different patterns ofweightloss can have on cancer risk.

Scarlett Sangster is a writer for PA Media Group

More on this topic

View original post here:
News digest prostate cancer MRI trial, drug delivery, cancer cures on Facebook and weight loss - Cancer Research UK - Science Blog

Posted in Hormone Replacement Therapy | Comments Off on News digest prostate cancer MRI trial, drug delivery, cancer cures on Facebook and weight loss – Cancer Research UK – Science Blog

Sinad OConnor review still nothing compares – The Guardian

Posted: December 25, 2019 at 12:43 pm

Throughout her every transformation, be it musical or visual, Sinad OConnor has remained instantly recognisable irreducibly herself. Wrapped in a black PVC mini-dress and sporting a bobbed wig on the cover of her last album, Im Not Bossy, Im The Boss (a long-ago 2014), the Irish singer was still identifiable as the shaven-headed young woman from the all-conquering Nothing Compares 2 U video, and as the pop star who tore up a picture of the pope on live US television in 1992.

A few days after her 53rd birthday, taking the stage on the only mainland UK date of her current tour, OConnor is barefoot, clad in a black abaya with a subtle geometric check, and wearing a hijab still unmistakable, despite a change in religion, two changes of name, some assertions of non-binary sexuality and a three-and-a-half-year process of regaining good mental health. Just as the Cassandra of Greek myth was doomed to tell the truth and not be believed, OConnors 1992 declarations about abuse in the Catholic church are now a very public scandal.

She is undergoing an act of renewal. Last year, she released a demo of new music under the name Magda Arjuna Davitt, expressing a desire to rid herself of her patriarchal slave name and parental curses. Now she goes by the name Shuhada Sadaqat (Shuhada is an Arabic girls name; sadaqat refers to a voluntary sign of faith).

Throughout, OConnor is a picture of restraint She still hits plenty of high notes, but she does it when it suits her

Even more striking than her shape-shifting constancy, perhaps, is the unwavering quality of her voice, which remains imbued with moral authority and the kind of tell-tale timbre that requires nanoseconds to recognise.

When OConnor she continues to use this name for work opens her mouth tonight to sing Queen of Denmark, a John Grant song that she has made her own, her voice still goes from nought-to-righteous ire in one breath. Why dont you take it out on somebody else? she hollers, to wild hoots of approval.

Throughout this often mesmerising gig, OConnor is a picture of restraint under-singing not because she has to, but because she is a master stylist. She still hits plenty of high notes, but she does it when it suits her. Also wonderfully unchanged is the way OConnor emphatically yanks her chin to one side on a crescendo, as though the full blare of her voice might overpower the microphone.

This tour which goes by the gnomic name 786 began with rave reviews in Ireland; it is set to continue, in bursts, well into 2020 as OConnor comes back into the world. Her timing has a little kismet about it. Uncompromising young women are no longer universally vilified, as OConnor was in the 90s. For all the abuse Greta Thunberg receives, her message and its unsmiling delivery resonates widely.

Most of OConnors compositions are love songs, but her political songs are now, once again, very relevant. Last summer, the US guitarist Sharon Van Etten revived one of OConnors old tunes, Black Boys on Mopeds. OConnors version goes down very well tonight. These are dangerous days, it goes (its set in the Thatcher era), and there are howls from the crowd, many of whom remember the last stretch of Tory hegemony first-hand.

Perhaps most germane to the present moment is OConnors very open, public and ongoing conversation about her physical and mental health. In 2017, she told a US television talk show that a hysterectomy in 2015 plunged her into full menopause, and OConnor cites the lack of hormone replacement therapy post-op as contributing to a suicide attempt.

That same year, the singer posted a distressed and distressing video from a New Jersey motel room. In the months that followed, she received in-patient therapy. She told the Irish broadcaster Dave Fanning last June that if I hadnt been in hospital for three and a half years I wouldnt be alive to sit here talking. She described therapeutic work undertaken on the trauma she sustained in childhood (her mother was a violent alcoholic who died when OConnor was 18) and the difficulty doctors had in arriving at her precise diagnosis.

Anyone following OConnors Twitter account lately will know she recently gave up smoking, broke a lumbar vertebra and is now selling her motorbike as a result. Happily, she is now also officially 99.999999% debt-free. There is new management two of her former bandmates and a memoir with a US publisher set to come out sometime after the US election, written in the style of a blog. There is talk also of not one, but two new albums. One looks set to be cover versions; the other might be called No Mud No Lotus, after the Buddhist idea that something of value comes out of suffering. Or it might be called AKA, given the frequent name changes.

Although every song OConnor serves up tonight emphatically has something to say, there are times when you do question the medium in which they are delivered. It is high time OConnor made a record that didnt have the foursquare thump of pop-rock at its heart her voice and her writing deserve something braver, more beautiful.

Backing her on this tour is a perfectly fine band of players beanpole electric guitarist Phil Edgar and sweet-voiced acoustic guitarist Jackie Rainey combine to sing harmonies with OConnor on In This Heart but the plodding metre feels dated, especially given the endless artistic possibilities of OConnors transcendental voice.

Harbour, from 2014, shows what she can do with a faintly jazzy blues. When she performs a cappella, however, time stands still. I Am Stretched on Your Grave is a traditional song OConnor recorded for I Do Not Want What I Havent Got (1990). Tonights version raises the hairs on your gooseflesh, with OConnors spectral voice soaring, and her intonation suggesting everything from traditional Celtic music to Arabic devotionals.

In 2015, OConnor retired Nothing Compares 2 U from her live repertoire, saying she didnt emotionally relate to the song any more. Its back, with new melismas and missing absolutely none of its heartbroken power. Even more shivery, however, is the moment in the encore, when OConnor starts her newest song, Milestones, without accompaniment and with the microphone switched off. Gradually, her voice rises and the amplification is turned back on. Evil is not my true nature, she sings. For a few pregnant seconds, this busy venue is in rapt silence.

Go here to see the original:
Sinad OConnor review still nothing compares - The Guardian

Posted in Hormone Replacement Therapy | Comments Off on Sinad OConnor review still nothing compares – The Guardian

Hormone Replacement Therapy (HRT) Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 – Info Street Wire

Posted: December 25, 2019 at 12:43 pm

The research study provided by UpMarketResearch on Global Hormone Replacement Therapy (HRT) Industry offers strategic assessment of the Hormone Replacement Therapy (HRT) market. The industry report focuses on the growth opportunities, which will help the market to expand operations in the existing markets.Next, in this report, you will find the competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. The Global Hormone Replacement Therapy (HRT) Market contains the ability to become one of the most lucrative industries as factors related to this market such as raw material affluence, financial stability, technological development, trading policies, and increasing demand are boosting the market growth. Therefore, the market is expected to see higher growth in the near future and greater CAGR during the forecast period from 2019 to 2026.

Request Exclusively Free Sample PDF Of This Report At https://www.upmarketresearch.com/home/requested_sample/12776

Major Players included in this report are as follows Abbott LaboratoriesNovartisPfizerMylan LaboratoriesMerck & Co.AmgenNovo NordiskBayerEli LilyWyethGenentech

Hormone Replacement Therapy (HRT) Market can be segmented into Product Types as OralParenteralTransdermalOthers

Hormone Replacement Therapy (HRT) Market can be segmented into Applications as MenopauseHypothyroidismMale HypogonadismGrowth Hormone DeficiencyOthers

Hormone Replacement Therapy (HRT) Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

Get Full Access with Complete ToC by purchasing This Report At https://www.upmarketresearch.com/buy/hormone-replacement-therapy-market

The Hormone Replacement Therapy (HRT) report regulates a complete analysis of the parent market including dependent and independent sectors. The report provides strategic recommendations with the senior analysts consultation that gives a clear perspective to clients as to which strategy will help them best to penetrate a market. Further, the report sheds light on the raw material sources, organizational structure, production processes, capacity utilization, value chain, pricing structure, technologies, equipment, product specifications distribution channel, and serving segments. It demonstrates graphical information with figures and pictures for elucidation.

For More Information on this report, Request Inquiry At https://www.upmarketresearch.com/home/enquiry_before_buying/12776

Key Highlights of This Report: The report covers Hormone Replacement Therapy (HRT) applications, market dynamics, and the study of emerging and existing market segments. It portrays market overview, product classification, applications, and market volume forecast from 2019-2026. It provides analysis on the industry chain scenario, key market players, market volume, upstream raw material details, production cost, and marketing channels. The growth opportunities, limitations to the market growth are identified using the SWOT analysis It conducts the feasibility study, explores the industry barriers, data sources and provides key research findings The report delivers analysis on consumption volume, region-wise import/export analysis and forecast market from 2019-2026.

For Best Discount on purchasing this report, Visit https://www.upmarketresearch.com/home/request_for_discount/12776

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected] Website https://www.upmarketresearch.com Address 500 East E Street, Ontario, CA 91764, United States.

This post was originally published on Info Street Wire

More:
Hormone Replacement Therapy (HRT) Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 - Info Street Wire

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy (HRT) Market 2019 Global Share, Trend, Segmentation and Forecast to 2025 – Info Street Wire

Star Wars: My Own Star Wars Story – Solzy at the Movies

Posted: December 25, 2019 at 12:43 pm

Ashley Eckstein took to the stage during Star Wars Celebration for Sisters of the Force to celebrate the women of the Star Wars universe.

Almost as soon as the voice of Ahsoka Tano took to the stage for the Sisters of the Force panel, she told the mostly female audience that Star Wars is for everyone. The actress couldnt be more right. All one has to do is look at the online vitriol. This has resulted in Star Wars actors deleting their social media accounts. After all, it only takes is a few bad apples to ruin the fun for everyone.I think back to the Episode IX panel. When Kelly Marie Tran was introduced, she got a rousing ovation and applause. This is the audience reminding the actress that theres still a fan base with love for her and her character, Rose. Eckstein would later invite Athena Portillo, Catherine Taber, Amy Ratcliffe, Vanessa Marshall, and Suzie McGrath to join her on stage.

We all have our own stories as to what draws us to the long-running saga. I may be a transgender woman but Im just as much of a Star Wars fan as I was before coming out a few years ago. My gender identity doesnt change my fandom. I think back to the surreal experience that I had when my name was called among the wait-listed outlets last year at SXSW for The Director and The Jedi red carpet. I did a double take as I could not believe that I got a spot on the red carpet. To be within feet of Luke Skywalker himselfMark Hamilland maybe even talk to him in person! Unfortunately, he went into the theater after tying his shoe. As such, he bypassed the four outlets standing on the side. But to be within a few feet of one of your heroes is absolutely insane!

We all have our own stories. Mine dates back to my cousin showing us Star Wars: A New Hope in the early 1990s. My uncle would later take my brother and myself to see the special editions in 1997. I only turned 12 a few months earlier. Prior to watching each film, my uncle would give me the original VHS tapes. This is the only version of the original trilogy that I own. By which, I mean before George Lucas started to make any changes. I would later get the Special Editions on VHS, DVD, and then on Blu-ray when the Star Wars saga was packaged together in 2011. These films combined with Jurassic Park set me on the path to a hopeful filmmaking career.

At the same time as I discovered the Star Wars franchise, I was making another discovery of my own. Well, I would have had the education and awareness been around. It was around the the same time when I wrote my first piece of trans fiction. I turned it in for homework without as much of a thought to it. Being a writer since as long as I can remember, Ive even dabbled in writing a Star Wars parody or two. I never really did the whole fan fiction thing. But beside that, my go-to wall calendar each year is either The Beatles or Star Wars. There may be a Marvel movie mixed in with the bunch but its almost always a Star Wars calendar.

I would start buying the books during middle school as well. As each movie came out, I would by the novel tie-ins to see what insight they offered. This was before the days of audio commentaries in DVD so I wanted to learn just how it was that Qui-Gonn Jinn became a force ghost. His body never disappeared like Obi-Wan Kenobi and Master Yoda. Unfortunately, the books at the time didnt offer much but I digress.

Ive watched the Star Wars films who knows how many times. As such, I do my best not to give into fear, anger, or hate because it could lead to the Dark Side. This is one of those lasting mantras that I try and associate with my daily life as a result of these films. Its because of this that I have to pull myself away from social media. Mostly because of self-care.

Im a big Padme fan mostly because of Natalie Portman more so than Catherine Taber in Star Wars: The Clone Wars. I grew up at a time when none of us really knew what being transgender meant because it wasnt really covered in the press. Funny enough, Ashley was having members of the panel share something they never shared before. Im about to open up so please bare with me.

When people asked me who my celebrity crushes were, I always said Natalie Portman. One could say that this was true from a certain point of view. The thing is, I wanted to BE her but refused to really admit my gender issues at the time. When you grow up as a straight girl in the wrong body, things can be super confusing. Society tells you to act in a way that deep down, your subconscious knows you shouldnt. So no, I never got to wear the Princess Leia buns or dress as Padme on Purim. Purim is the Jewish holiday where people dress in costumes. Coming to terms with myself wouldnt happen until a few weeks before the release of The Force Awakens. It would not be an understatement to say that shit hit the fan.

Let me tell you, my first time watching The Force Awakens was not easy because the dysphoria was awful in December 2015. Like I knew I needed to have already started on hormone replacement therapy but the reality was that this is easier said than done. Watching the film prior to seeing The Last Jedi went much better because most of those dysphoric feelings were largely gone or invisible. They still get bad from time to time. However, its nothing like the dysphoric depression that nearly killed me. I will say how excited I was to see Daisy Ridleys Rey following in Carrie Fishers footsteps. One of the reasons why Star Wars works is because of these kick-ass heroines. Just as the Force was awkening in Rey, something else entirely different was awakening within me after years of repression.

A few weeks before Rogue One was released, I was really struggling with depression during the first week of November. I know exactly what Vanessa Marshall means when she spoke about her depression struggles. Even though I had just changed my name, I was homesick and my family had just put down our 16-year old border collie/husky mix before I had the chance to say goodbye. Moreover, when youre the rare St. Louis Cardinals fan living less than a mile from Wrigley Field, the week became super depressing because the Cubs went on to win the 2016 World Series. I was a real mess when I saw Doctor Strange but what started to turn things around was seeing the signage for Rogue One and knowing that were getting a live-action take on the Star Wars: A New Hope opening crawl. This gave me hope and something to look forward to.

Getting the opportunity to attend and cover my first Star Wars Celebration was amazing. While I didnt have the finances to shell out on the photos or autographs that I wanted, the one positive highlight of not winning the Episode IX lottery was winning a limited ticket for a photo with Anthony Daniels. While Luke Skywalker walked a few feet in front of me last year, meeting C-3PO himself during Celebration is an opportunity Ill never forget.

During Wizard World Chicago in August, I got to meet and chat with Greg Grunberg, who appeared in the sequel trilogy.

Finally, there was the moment that came during the Toronto International Film Festival when I got to formally meet writer-director Rian Johnson (Go see Knives Out!) at the world premiere of Jojo Rabbit:

May the Force be with you!

Related

More:
Star Wars: My Own Star Wars Story - Solzy at the Movies

Posted in Hormone Replacement Therapy | Comments Off on Star Wars: My Own Star Wars Story – Solzy at the Movies

Page 1,215«..1020..1,2141,2151,2161,217..1,2201,230..»